- Case report
- Open Access
- Open Peer Review
Radiological, pathological and DNA remission in recurrent metastatic nasopharyngeal carcinoma
BMC Cancer volume 6, Article number: 259 (2006)
Circulating plasma Epstein Barr Virus DNA (EBV-DNA) is a sensitive and specific marker of nasopharyngeal carcinoma (NPC). The mainstay of treatment of metastatic NPC is systemic chemotherapy and resection for solitary metastasis. Despite high response rate to chemotherapy, complete remission is uncommonly seen.
We report a case of recurrent metastatic NPC in a 43-year-old man, who achieved complete remission three times with chemotherapy and surgery. Serial plasma EBV-DNA levels were measured during the course of disease. The patient had three episodes of recurrences of NPC manifested as distant metastasis. Both time, rise in the plasma EBV-DNA level preceded detection of recurrences by imaging. Following systemic chemotherapy, he achieved complete remission each time, of which was confirmed by 18-flourodeoxyglucose positron emission tomography and hepatectomy pathology. The plasma EBV-DNA level dropped to zero copy/ml at the time of each remission.
This case highlights the high chemosensitivity of NPC by illustrating a rare occurrence of complete response of metastatic NPC to chemotherapy. This case also underscores the usefulness of EBV-DNA as a useful tool in monitoring NPC by its ability to detect early recurrence and excellent correlation with treatment response.
The recent development in nucleic acids in serum and plasma has opened up many new areas in molecular diagnosis. In the field of oncology, circulating plasma/serum Epstein Barr Virus (EBV) DNA in nasopharyngeal carcinoma (NPC) is a good example. The real-time polymerase chain reaction (RT-PCR) is a reliable and reproducible technique, which allows a rapid quantification of plasma EBV DNA, thus rendering it an attractive tool in the monitoring of treatment response [1, 2]. The test is highly sensitive because it targets the BamHI-W repeat region of the EBV genome . This test became available for clinical use at our oncology centre in 2002. Though it is uncommon to see patients with metastatic NPC achieve partial response to chemotherapy, it is very rare to observe complete response. Here we report a case which illustrates rare occurrence of complete response to chemotherapy and highlights good correlation between plasma EBV DNA and FDG-PET scan and pathology. Written consent was obtained from the patient for publication of this report.
A 43-year old man was referred to our cancer center in October, 2001 with stage IIb undifferentiated nasopharyngeal carcinoma (T2N1M0). He completed radical radiotherapy in December, 2001, and achieved complete remission afterwards. Although baseline plasma EBV DNA was not available, patient had undetectable plasma EBV DNA which was measured within one week after radiotherapy.
Upon a routine follow-up in August, 2002, the patient developed with an asymptomatic rise in the plasma EBV DNA level at 129,437 copies/ml. A subsequent FDG-positron emission and computered tomography fusion scan (FDG-PET-CT) showed a 4 cm hypermetabolic solitary metastasis in the right lobe of liver with a FDG standard uptake value (SUV) of 7.6 (Figure 1). Following treatment with six courses of paclitaxel and carboplatin chemotherapy, his plasma EBV DNA level fell to undetectable level, and a subsequent PET-CT performed immediately after completion of chemotherapy confirmed a reduction in the size and SUV of the liver metastasis (Figure 1). A right hepatectomy was performed at two weeks after the end of chemotherapy, and pathological examination of the resected specimen showed necrotic tissues without any evidence of viable malignant cells.
The patient enjoyed a disease-free period of about nine months until a second disease relapse in September, 2003, when he was found to have asymptomatic rise in plasma EBV-DNA level to 678 copies/ml. A subsequent PET-CT confirmed multiple hyper-metabolic recurrences in the liver, lung and pancreatic head (Figure 2). After 2 courses of second-line chemotherapy with gemcitabine and carboplatin, his plasma EBV DNA level fell to undetectable level which coincided with complete disappearance of metastatic lesions (i.e. complete remission) on PET-CT in October, 03 (Figure 2). He completed a total of 4 cycles of gemcitabine and carboplatin and remained disease-free until 4 months later in February 2004, when he developed a third relapse which was heralded by an asymptomatic and progressive rise in plasma EBV-DNA levels from 56 to 329 copies/ml over a 2 month period. A PET-CT performed in April 2004 confirmed recurrence in the liver and pancreatic head. He was re-treated with 6 cycles of gemcitabine and carboplatin chemotherapy, and again, his plasma EBV-DNA level became undetectable and PET/CT showed complete remission. Upon his last follow-up in November 2004, he remained disease-free for 7 months following the last chemotherapy treatment in 2004.
In our patient, rising levels of plasma EBV DNA was consistently associated with evidence of distant recurrence as indicated objectively on PET-CT imaging (Figure 3 & Table 1), before the development of any clinical signs or symptoms of relapse. Second, radiological evidence of complete response (delineated by FDG-PET) to chemotherapy also coincided consistently with undetectable levels of plasma EBV DNA. We did not perform histological confirmation of PET-CT detected disease recurrence because the location and SUV intensity of those abnormalities were unlikely due to false-positive or inflammatory causes. Furthermore, studies have shown that PET is sensitive and specific in detecting recurrent nasopharyngeal carcinoma [3, 4].
It is observed that patient subsequently developed recurrences though plasma EBV DNA dropped to zero copy/ml when he was having a relatively inactive disease (which is manifested as clinical and radiological remission). This is unlikely due to suboptimal EBV DNA assay because the assay used by our centre is well validated as reported previously [1, 2, 5]. It is noteworthy that although plasma EBV DNA is a sensitive tool in monitoring disease and tumor burden, zero copy/ml of EBV DNA does not necessarily equate complete eradication of disease, and close monitoring of clinical condition and EBV DNA level are still required. The case study also points to the importance of a well standardized and highly sensitive PCR method, because the relatively low level of EBV DNA detected in second and third relapse might be missed with a less sensitive PCR method [1, 10].
Cell-free EBV DNA was first demonstrated in circulation of NPC patient by PCR amplification in 1998 . Dependent on number of PCR cycles, modalities of PCR and various preparations of specimen, different assays of various sensitivity and specificity were subsequently developed for detection of circulating EBV DNA [1, 7–10]. Several characteristics have enabled circulating EBV DNA to be widely used in clinical practice for management of NPC. In our institute, with the use of real time PCR, EBV DNA in plasma had been demonstrated to be a both sensitive (96%) and specific (93%) marker of NPC . EBV DNA is undetectable in healthy individuals and those disease-free patients with history of NPC, while it is raised in plasma of most patients with active disease. Also, plasma EBV DNA has a role in staging and prognostication [11, 12]: higher level of EBV DNA is detected in patient with more advanced UICC stage, and those patients with non-metastatic NPC have poorer prognosis when there is persistent high EBV DNA level after radical radiotherapy to nasopharynx. More importantly, detection of EBV DNA can be used for monitoring of NPC patients for any recurrence or metastasis [2, 13]. It had been reported by that rise in EBV DNA might predate clinical relapse up to few months hence rendering earlier work-up and treatment feasible . Other potential use of circulating EBV DNA remains to be elucidated. For example, the use of EBV DNA in screening general population for NPC is still under active research. There are also ongoing studies addressing the improved accuracy of detecting NPC with combined use of circulating EBV DNA and other serological markers. In our centre, we have already completed a prospective study looking into correlation between plasma EBV DNA and PET-CT imaging before and after radiotherapy in patients with advanced NPC. With this case, apart from reporting an uncommon occurrence of chemotherapy induced complete remission of metastatic nasopharyngeal carcinoma, we hope this case can highlight the good correlation between circulating EBV DNA and FDG-PET scan in disease monitoring of nasopharyngeal carcinoma.
Lo YM, Chan LY, Lo KW, Leung SF, Zhang J, Chan AT, Lee JC, Hjelm NM, Johnson PJ, Huang DP: Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res. 1999, 59: 1188-1191.
Chan AT, Lo YM, Zee B, Chan LY, Ma BB, Leung SF, Mo F, Lai M, Ho S, Huang DP, Johnson PJ: Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst. 2002, 94: 1614-1619.
Yen RF, Hong RL, Tzen KY, Pan MH, Chen TH: Whole-body 18F-FDG PET in recurrent or metastatic nasopharyngeal carcinoma. J Nucl Med. 2005, 46: 770-774.
Kao CH, Hsieh JF, Tsai SC, Ho YJ, Yen RF, ChangLai SP, Chieng PU: Comparison of 18-fluoro-2-deoxyglucose positron emission tomography and computed tomography in detection of cervical lymph node metastasis of nasopharyngeal carcinoma. Ann Otol Rhinol Laryngol. 2000, 109: 1130-1134.
Lo YM, Leung SF, Chan LY, Lo KW, Zhang J, Chan AT, Lee JC, Hjelm NM, Johnson PJ, Huang DP: Plasma cell-free Epstein-Barr virus DNA quantitation in patients with nasopharyngeal carcinoma. Correlation with clinical staging. Ann N Y Acad Sci. 2000, 906: 99-101.
Mutirangura A, Pornthanakasem W, Theamboonlers A, Sriuranpong V, Lertsanguansinchi P, Yenrudi S, Voravud N, Supiyaphun P, Poovorawan Y: Epstein-Barr viral DNA in serum of patients with nasopharyngeal carcinoma. Clin Cancer Res. 1998, 4: 665-669.
Hsiao JR, Jin YT, Tsai ST: Detection of cell free Epstein-Barr virus DNA in sera from patients with nasopharyngeal carcinoma. Cancer. 2000, 94: 723-729. 10.1002/cncr.10251.
Shotelersuk K, Khorprasert C, Sakdikul S, Pornthanakasem W, Voravud N, Mutirangura A: Epstein-Barr virus DNA in serum/plasma as a tumor marker for nasopharyngeal cancer. Clin Cancer Res. 2000, 6: 1046-1051.
Chan KH, Gu YL, Ng F, Ng PS, Seto WH, Sham JS, Chua D, Wei W, Chen YL, Luk W, Zong YS, Ng MH: EBV specific antibody-based and DNA-based assays in serologic diagnosis of nasopharyngeal carcinoma. Int J Cancer. 2003, 105: 706-709. 10.1002/ijc.11130.
Stevens SJ, Verkuijlen SA, Hariwiyanto B, Harijadi , Fachiroh J, Paramita DK, Tan IB, Haryana SM, Middeldorp JM: Diagnostic value of measuring Epstein-Barr virus (EBV) DNA load and carcinoma-specific viral mRNA in relation to anti-EBV immunoglobulin A (IgA) and IgG antibody levels in blood of nasopharyngeal carcinoma patients from Indonesia. J Clin Microbiol. 2005, 43: 3066-3073. 10.1128/JCM.43.7.3066-3073.2005.
Lo YM, Chan AT, Chan LY, Leung SF, Lam CW, Huang DP, Johnson PJ: Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. Cancer Res. 2000, 60: 6878-6881.
Lo YM, Chan LY, Chan AT, Leung SF, Lo KW, Zhang J, Lee JC, Hjelm NM, Johnson PJ, Huang DP: Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res. 1999, 59: 5452-5455.
Lin JC, Wang WY, Chen KY, Wei YH, Liang WM, Jan JS, Jiang RS: Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med. 2004, 350: 2461-2470. 10.1056/NEJMoa032260.
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/6/259/prepub
Written consent was obtained from the patient for publication of this report.
The authors are indebted to the patient for providing informed consent and giving kind permission of this report.
The author(s) declare that they have no competing interests.
SLC Patient care, Concept & design, Preparation of manuscript
EPH Patient care, Critical revision
SFL Patient care, Critical revision
ATCC Patient care, Critical revision
BBYM Patient Care, Concept & design, Final revision
All authors read and approved the final manuscript
About this article
Cite this article
Chan, S.L., Hui, E.P., Leung, S.F. et al. Radiological, pathological and DNA remission in recurrent metastatic nasopharyngeal carcinoma. BMC Cancer 6, 259 (2006) doi:10.1186/1471-2407-6-259
- Standard Uptake Value
- Nasopharyngeal Carcinoma
- Epstein Barr Virus Genome
- Carboplatin Chemotherapy